Ionis Pharmaceuticals, Inc. (IONS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:41AM EDT. Market open.
| Previous close | 43.09 |
| Open | 43.54 |
| Bid | 43.09 x 400 |
| Ask | 43.37 x 200 |
| Day's range | 43.17 - 43.76 |
| 52-week range | 34.79 - 54.44 |
| Volume | |
| Avg. volume | 1,072,582 |
| Market cap | 6.306B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
© 2024 Yahoo. All rights reserved.